[HTML][HTML] Prognostic implications of pericardial and pleural effusion in patients with cardiac amyloidosis

C Binder, F Duca, T Binder, R Rettl, TM Dachs… - Clinical Research in …, 2021 - Springer
Background Pericardial and pleural effusion are common findings in patients with cardiac
amyloidosis (CA). It is not known, whether effusions correlate with right ventricular (RV) …

Machine learning-derived electrocardiographic algorithm for the detection of cardiac amyloidosis

L Schrutka, P Anner, A Agibetov, B Seirer, F Dusik… - Heart, 2022 - heart.bmj.com
Background Diagnosis of cardiac amyloidosis (CA) requires advanced imaging techniques.
Typical surface ECG patterns have been described, but their diagnostic abilities are limited …

[HTML][HTML] Machine learning enables prediction of cardiac amyloidosis by routine laboratory parameters: a proof-of-concept study

A Agibetov, B Seirer, TM Dachs, M Koschutnik… - Journal of Clinical …, 2020 - mdpi.com
(1) Background: Cardiac amyloidosis (CA) is a rare and complex condition with poor
prognosis. While novel therapies improve outcomes, many affected individuals remain …

[HTML][HTML] Renin feedback is an independent predictor of outcome in HFpEF

C Binder, M Poglitsch, F Duca, R Rettl… - Journal of Personalized …, 2021 - mdpi.com
Drugs which interact with the renin angiotensin aldosterone system (RAAS) aim to reduce
the negative effects of angiotensin (Ang) II. Treatment with these drugs anticipate a …

[HTML][HTML] What type of patients did PARAGON-HF select? Insights from a real-world prospective cohort of patients with heart failure and preserved ejection fraction

R Rettl, TM Dachs, F Duca, C Binder, F Dusik… - Journal of Clinical …, 2020 - mdpi.com
The PARAGON-HF clinical trial suggested that sacubitril/valsartan may become a treatment
option for particular subgroups of patients with heart failure and preserved ejection fraction …

[HTML][HTML] Patients with heart failure and preserved ejection fraction are at risk of gastrointestinal bleeding

L Schrutka, B Seirer, F Duca, C Binder, D Dalos… - Journal of Clinical …, 2019 - mdpi.com
Aims. Two thirds of patients with heart failure and preserved ejection fraction (HFpEF) have
an indication for oral anticoagulation (OAC) to prevent thromboembolic events. However …

[HTML][HTML] Hemodynamic profiles and their prognostic relevance in cardiac amyloidosis

F Duca, A Snidat, C Binder, R Rettl, TM Dachs… - Journal of Clinical …, 2020 - mdpi.com
This study sought to characterize cardiac amyloidosis (CA) patients with respect to
hemodynamic parameters and asses their prognostic impact in different CA cohorts …

[HTML][HTML] Heart failure with preserved ejection fraction: Calculating the risk of future heart failure events and death

L Schrutka, B Seirer, R Rettl, TM Dachs… - Frontiers in …, 2022 - frontiersin.org
Objective. We sought to develop a clinical model to identify heart failure patients with
preserved ejection fraction (HFpEF) at highest risk for acute HF events or death. Methods …

High Filling Pressures and Risk for Bleeding Events in Patients With Atrial Fibrillation and Heart Failure With Preserved Ejection Fraction

L Schrutka, B Seirer, F Duca, C Binder, C Nitsche… - Circulation, 2018 - Am Heart Assoc
Introduction: Two thirds of patients with heart failure and preserved ejection fraction (HFpEF)
suffer from atrial fibrillation (AF) and use of oral anticoagulants (OAC) is recommended …

Recurrent heart failure hospitalizations in patients with preserved ejection fraction: predictors and outcome

L Schrutka, B Seirer, F Frommlet, C Binder… - European Heart …, 2021 - academic.oup.com
Background Heart failure with preserved ejection fraction (HFpEF) is the most common form
of HF and its prevalence is approaching epidemic proportions. Current treatment strategies …